TABLE 2.
Subject disposition
| Reason subjects discontinued study drugs | No. of subjects (%)
|
|
|---|---|---|
| d4T-3TC-IDV | AZT-3TC-IDV | |
| Before wk 80 | 15 (18) | 24 (28) |
| Lost to follow-up | 1 (1) | 1 (1) |
| Death | 2 (2) | 0 |
| Adverse events | 7 (8) | 11 (13) |
| Subject request | 2 (2) | 3 (4) |
| Virological failure | 1 (1) | 6 (7) |
| Physician decision | 0 | 1 (1) |
| Other reason or unknown | 2 (2) | 2 (2) |
| During the extended follow-up | 9 (16) | 13 (22) |
| Lost to follow-up | 0 | 1 (2) |
| Death | 1 (2) | 0 |
| Adverse events | 4 (7) | 0 |
| Subject request | 0 | 4 (7) |
| Virological failure | 0 | 0 |
| Physician decision | 3 (5) | 2 (3) |
| Other reason or unknown | 1 (2) | 6 (10) |